All relevant data are within the manuscript and its Supporting Information files.

Introduction {#sec001}
============

Antibodies can bind with strong affinity and exquisite specificity to a multitude of antigens. Due to their clinical and commercial success, antibodies are one of the largest and fastest growing classes of therapeutic drugs \[[@pcbi.1007830.ref001]\]. While most therapies currently use monoclonal antibodies (mAbs), mounting evidence suggests that mixtures of antibodies can lead to better control through improved breadth, potency, and effector functions \[[@pcbi.1007830.ref002]\]. There is ample precedent for the idea that combinations of therapeutics can be extremely powerful---for instance, during the past 50 years the monumental triumphs of combination anti-retroviral therapy and chemotherapy cocktails have provided unprecedented control over HIV and multiple types of cancer \[[@pcbi.1007830.ref003], [@pcbi.1007830.ref004]\], and in many cases no single drug has emerged with comparable effects. However, it is difficult to predict how antibody mixtures will behave relative to their constitutive parts. Often, the vast number of potential combinations is prohibitively large to systematically test, since both the composition of the mixture and the relative concentration of each component can influence its efficacy \[[@pcbi.1007830.ref005]\].

Here, we develop a statistical mechanical model that bridges the gap between how an antibody operates on its own and how it behaves in concert. Specifically, each antibody is characterized by its binding affinity and potency, while its interaction with other antibodies is described by whether its epitope is distinct from or overlaps with theirs. This information enables us to translate the molecular details of how each antibody acts individually into the macroscopic readout of a system's activity in the presence of an arbitrary mixture.

To test the predictive power of our framework, we apply it to a beautiful recent case study of inhibitory antibodies against the epidermal growth factor receptor (EGFR), where 10 antibodies were individually characterized for their ability to inhibit receptor activity and then all possible 2-Ab and 3-Ab mixtures were similarly tested \[[@pcbi.1007830.ref006]\]. We demonstrate that our framework can accurately predict the activity of these mixtures based solely on the behaviors of the ten monoclonal antibody as well as their epitope mappings.

Lastly, we generalize our model to predict the potency of engineered multidomain antibodies from their individual components. Specifically, we consider the recent work by Laursen *et al*. where four single-domain antibodies were assayed for their ability to neutralize a panel of influenza strains, and then the potency of constructs comprising 2-4 of these single-domain antibodies were measured \[[@pcbi.1007830.ref007]\]. Our generalized model can once again predict the efficacy of the multidomain constructs based upon their constitutive components, once a single fit parameter is inferred to quantify the effects of the linker joining the single-domain antibodies. This enables us to quantitatively ascertain how tethering antibodies enhances the two key features of potency and breadth that are instrumental for designing novel anti-viral therapeutics.

Notably, while we discuss how synergistic interactions could be introduced to increase the model's accuracy at the cost of additional complexity and fit parameters, the success of our simple models suggest that many antibody mixtures function without synergy, and hence that their effects can be computationally predicted to expedite future experiments.

Results {#sec002}
=======

Modeling the mechanisms of action for antibody mixtures {#sec003}
-------------------------------------------------------

Consider a monoclonal antibody that binds to a receptor and inhibits its activity. Two parameters characterize this inhibition: (1) the dissociation constant *K*~*D*~ quantifies an antibody's binding affinity (with a smaller value indicating tighter binding) and (2) the potency *α* relates the activity when an antibody is bound to the activity in the absence of antibody. A value of *α* = 1 represents an impotent antibody that does not affect activity while *α* = 0 implies that an antibody fully inhibits activity upon binding. Antibodies with an intermediate value (0 \< *α* \< 1) will partially inhibit receptor activity upon binding \[[@pcbi.1007830.ref008]\], whereas antibodies with potency greater than one (*α* \> 1) will increase activity upon binding \[[@pcbi.1007830.ref005]\]. As derived in [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section A.1, for an antibody that binds to a single site on a receptor, the activity at a concentration *c* of antibody is given by $$\begin{array}{r}
{\text{Fractional}\mspace{720mu}\text{Activity} = \frac{1 + \alpha\frac{c}{K_{D}}}{1 + \frac{c}{K_{D}}}.} \\
\end{array}$$

To characterize a mixture of two antibodies, we not only need their individual dissociation constants and potencies but also require a model for how these antibodies interact. When two antibodies bind to distinct epitopes, the simplest scenario is that their ability to bind and inhibit activity is independent of the presence of the other antibody, and hence that their combined potency when simultaneously bound equals the product of their individual potencies ([Fig 1A](#pcbi.1007830.g001){ref-type="fig"}) \[[@pcbi.1007830.ref009], [@pcbi.1007830.ref010]\]. Alternatively, if the two antibodies compete for the same epitope, they cannot both be simultaneously bound ([Fig 1B](#pcbi.1007830.g001){ref-type="fig"}) \[[@pcbi.1007830.ref011]\].

![Binding modes for a 2-Ab mixture.\
Two antibodies with concentrations *c*~1~ and *c*~2~ can bind (A) independently to different epitopes or (B) competitively to the same epitope. (C) Antibodies bind synergistically if either the product of binding affinities ($K_{D}^{(j)}$) or potencies (*α*~*j*~) are altered when both antibodies bind.](pcbi.1007830.g001){#pcbi.1007830.g001}

We also define the general case of a synergistic interaction where the binding of the first antibody alters the binding or potency of the second antibody ([Fig 1C](#pcbi.1007830.g001){ref-type="fig"}, purple text). This definition encompasses cases where the second antibody binds more tightly ($K_{D,\text{eff}}^{(2)} < K_{D}^{(2)}$) or more weakly ($K_{D,\text{eff}}^{(2)} > K_{D}^{(2)}$) in the presence of the first antibody, as well as when the potency of the second antibody may increase (*α*~2,eff~ \> *α*~2~) or decrease (*α*~2,eff~ \< *α*~2~). This also includes cases where two epitopes slightly overlap and partially inhibit one another's binding, and the competitive binding model can be viewed as the extreme limit $\left. K_{D,\text{eff}}^{(2)}\rightarrow\infty \right.$ where one antibody infinitely penalizes the binding of the other.

While the synergistic model in [Fig 1C](#pcbi.1007830.g001){ref-type="fig"} has the merit of being highly general, an important feature of the independent and competitive models ([Fig 1A and 1B](#pcbi.1007830.g001){ref-type="fig"}) is that they predict all antibody combinations with few parameters. In both of these latter models, once the $K_{D}^{(j)}$ and *α*~*j*~ of 10 antibodies are known (which requires 2 ⋅ 10 experiments) and their epitopes are mapped by pairwise interactions ($\frac{10 \cdot 9}{2}$ additional experiments), the potency of all 2^10^ = 1024 possible mixtures of these antibodies can be predicted without recourse to fitting. In contrast, because the synergistic model allows arbitrary interactions between each combination of antibodies, the behavior of a mixture exhibiting synergy cannot be predicted without actually making a measurement on that combination to quantify the synergy.

For these reasons, in this work we focus on the two cases of independent or competitive binding and show how we can combine both models to transform our molecular understanding of each monoclonal antibody's action into a prediction of the efficacy of an antibody mixture. Deviations from our predictions provide a rigorous way to measure antibody synergy by computing $\frac{K_{D,\text{eff}}^{(2)}}{K_{D}^{(2)}}$ and $\frac{\alpha_{2,\text{eff}}}{\alpha_{2}}$.

To mathematize the independent and competitive binding models, we enumerate the possible binding states and compute their relative Boltzmann weights. The fractional activity of each state equals the product of its relative probability and relative activity divided by the sum of all relative probabilities for normalization (see [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section A.1). When two antibodies bind independently as in [Fig 1A](#pcbi.1007830.g001){ref-type="fig"}, this factors into the form $$\begin{array}{r}
{\text{Fractional}\mspace{720mu}\text{Activity}_{(\text{distinct}\mspace{720mu}\text{epitopes})} = \left( \frac{1 + \alpha_{1}\frac{c_{1}}{K_{D}^{(1)}}}{1 + \frac{c_{1}}{K_{D}^{(1)}}} \right)\left( \frac{1 + \alpha_{2}\frac{c_{2}}{K_{D}^{(2)}}}{1 + \frac{c_{2}}{K_{D}^{(2)}}} \right).} \\
\end{array}$$

If these two antibodies compete for the same epitope as in [Fig 1B](#pcbi.1007830.g001){ref-type="fig"}, the activity becomes $$\begin{array}{r}
{\text{Fractional}\mspace{720mu}\text{Activity}_{(\text{overlapping}\mspace{720mu}\text{epitopes})} = \frac{1 + \alpha_{1}\frac{c_{1}}{K_{D}^{(1)}} + \alpha_{2}\frac{c_{2}}{K_{D}^{(2)}}}{1 + \frac{c_{1}}{K_{D}^{(1)}} + \frac{c_{2}}{K_{D}^{(2)}}}.} \\
\end{array}$$

These equations are readily extended to mixtures with three or more antibodies (see [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section A.2).

Antibody mixtures against EGFR are well characterized using independent and competitive binding models {#sec004}
------------------------------------------------------------------------------------------------------

To test the predictive power of the independent and competitive binding models, we applied them to published experiments on the epidermal growth factor receptor (EGFR) where ten monoclonal antibodies were individually characterized and then the activity of all 165 possible 2-Ab and 3-Ab mixtures was measured \[[@pcbi.1007830.ref006]\]. We first use each monoclonal antibody's response to infer its dissociation constant *K*~*D*~ and potency *α*. We then utilize surface plasmon resonance (SPR) measurements to determine which pairs of antibodies bind independently and which compete for the same epitope. These data enable us to use the above framework and predict EGFR activity in the presence of any mixture.

EGFR is a transmembrane protein that activates in the presence of epidermal growth factors. Upon ligand binding, the receptor's intracellular tyrosine kinase domain autophosphorylates which leads to downstream signaling cascades central to cell migration and proliferation. Overexpression of EGFR has been linked to a number of cancers, and decreasing EGFR activity in such tumors by sterically occluding ligand binding has reduced the rate of cancer proliferation \[[@pcbi.1007830.ref006]\].

Koefoed *et al*. investigated how a panel of ten monoclonal antibodies inhibit EGFR activity in the human cell line A431NS \[[@pcbi.1007830.ref006]\]. They then measured how 1:1 mixtures of two antibodies or 1:1:1 mixtures of three antibodies affect EGFR activity. All measurement were carried out at a total concentration of $2\frac{\mu\text{g}}{\text{mL}}$, implying that each antibody was half as dilute in the 2-Ab mixtures and one-third as dilute in the 3-Ab mixtures relative to the monoclonal antibody measurement.

The 45 possible 2-Ab mixtures (35 binding to distinct epitopes; 10 binding to overlapping epitopes) and the 120 possible 3-Ab mixtures (50 binding to distinct epitopes; 70 binding to overlapping epitopes) were assayed for their ability to inhibit EGFR activity. [Fig 2A](#pcbi.1007830.g002){ref-type="fig"} shows the experimental measurements for mixtures of two antibodies, with the monoclonal antibody measurements shown on the diagonal, the measured activity of 2-Ab mixtures shown on the bottom-left, and the predicted activity on the top-right. The labels on the diagonal entries denote each antibody's binding epitopes inferred through SPR \[[@pcbi.1007830.ref006]\], so that antibodies binding to overlapping epitopes are predicted using [Eq (3)](#pcbi.1007830.e012){ref-type="disp-formula"} (pairs within the dashed gray boxes) while mixtures binding to distinct epitopes use [Eq (2)](#pcbi.1007830.e011){ref-type="disp-formula"}.

For example, antibodies \#1 and \#4 bind to distinct epitopes (III/C and III/B, respectively). Hence, the predicted activity of their mixture (0.50) very nearly equals the product of their individual activity (0.65 × 0.75 = 0.49), with the slight deviation arising because each antibody concentration was halved in the mixture ($c_{1} = c_{2} = 1\frac{\mu\text{g}}{\text{mL}}$ for the 2-Ab mixture characterized by [Eq (2)](#pcbi.1007830.e011){ref-type="disp-formula"}, whereas the individual mAbs were measured at $c = 2\frac{\mu\text{g}}{\text{mL}}$ using [Eq (1)](#pcbi.1007830.e002){ref-type="disp-formula"}). This predicted activity roughly approximates the measured value 0.43 of the mixture.

![Predicting how antibody mixtures affect the epidermal growth factor receptor (EGFR).\
(A) The fractional activity of EGFR in the presence of monoclonal antibodies (diagonal) together with the measured (bottom-left) and predicted (top-right) activity of all 2-Ab combinations. The dashed gray boxes enclose antibody pairs that compete for the same epitope while all other pairs bind independently. (B) The predicted versus measured fractional activity for all 2-Ab (circles) and 3-Ab mixtures (triangles) using the same epitope mapping as in Panel A inferred by SPR. Without the epitope map, the activity of the mixtures could alternately be predicted by assuming that all antibodies either (C) bind independently or (D) compete for the same epitope; in either case, the resulting predictions fall further from the diagonal line, indicating poorer predictive power. Data was digitized from Table.1 and Fig S1 of Ref. \[[@pcbi.1007830.ref006]\].](pcbi.1007830.g002){#pcbi.1007830.g002}

On the other hand, antibodies \#1 and \#2 bind to the same epitope (III/C), and hence their predicted combined activity (0.67) lies between their individual activities (0.65 and 0.69) since both antibodies compete for the same site. The measured activity of the mixture (0.65) closely matches the prediction of the overlapping epitope model, but is very different than the prediction of 0.45 made by the distinct-binding model.

[Fig 2B](#pcbi.1007830.g002){ref-type="fig"} shows the measured EGFR activity in the presence of all 2-Ab and 3-Ab mixtures is highly correlated with the predicted activity (*R*^2^ = 0.90) Notably, the predictions are made solely from the monoclonal antibody data and epitope measurements, and do not involve any fitting of the 2-Ab or 3-Ab measurements. The strong correlation between the predicted and measured activities suggests that EGFR antibody mixtures can be characterized with minimal synergistic effects in either their binding or effector functions. If we did not have the epitope mapping through SPR and assumed that all antibodies bound to distinct epitopes ([Fig 2C](#pcbi.1007830.g002){ref-type="fig"}, *R*^2^ = 0.85) or competed for the same epitope ([Fig 2D](#pcbi.1007830.g002){ref-type="fig"}, *R*^2^ = 0.86), the resulting predictions are slightly more scattered from the diagonal, demonstrating that properly acknowledging which pairs of antibodies vie for the same epitope boosts the predictive power of the model.

That said, the predictions incorporating the SPR mapping display a consistent bias towards having a slightly lower measured than predicted activity (Fig E in [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"}), suggesting that several pairs of antibodies enhance one another's binding affinity or potency. To quantify this effect, we recharacterized the activity from the 2-Ab mixtures using a synergistic model where each *α*~2,eff~ is fit to exactly match the data. We find an average value of $\frac{\alpha_{2,\text{eff}}}{\alpha_{2}} = 0.9$, showing that when pairs of antibodies are simultaneously bound they typically boost their collective inhibitory activity by ∼10%. This increase in the potency of antibody mixtures could arise from allosteric interactions where the binding of one antibody stabilizes a binding-favorable conformation for another antibody \[[@pcbi.1007830.ref012]--[@pcbi.1007830.ref014]\].

Differentiating distinct versus overlapping epitopes using antibody mixtures {#sec005}
----------------------------------------------------------------------------

In the previous section, we used SPR measurements to quantify which antibodies compete for overlapping epitopes, thereby permitting us to translate the molecular knowledge of antibody interactions into a macroscopic quantity of interest, namely, the activity of EGFR. In this section, we do the reverse and utilize activity measurements to categorize which subsets of antibodies bind to overlapping epitopes. This method can be applied to model antibody mixtures in other biological systems where SPR measurements are not readily available.

For the remainder of this section, we ignore the known epitope mappings discerned by Koefoed *et al*. and consider what mapping best characterizes the data. For example, given the individual activities of antibody \#1 (0.65) and \#2 (0.69), the predicted activity of their combination (at the concentration of $1\frac{\mu\text{g}}{\text{mL}}$ for each antibody dictated by the experiments) would be 0.45 if they bind to distinct epitopes and 0.67 if they bind to overlapping epitopes. Since the measured activity of this mixture was 0.65, it suggests the latter option. We note that such analysis will work best for potent antibodies (whose individual activity is far from 1), since only in this regime will the predictions of the distinct versus overlapping models be significantly different. Therefore, the activity measurements of each individual antibody would optimally be carried out at saturating concentrations (where [Eq (1)](#pcbi.1007830.e002){ref-type="disp-formula"} is as far from 1 as possible).

Proceeding to the other antibodies, we characterize each pair according to whichever model prediction lies closer to the experimental measurement. To account for experimental error, we left an antibody pair uncategorized if the two model predictions were too close to one another (within 4*σ* = 0.16 where *σ* is the SEM of the measurements) or if the experimental measurement was close (within 1*σ*) to the average of the two model predictions (see [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section B).

[Fig 3A](#pcbi.1007830.g003){ref-type="fig"} shows how this analysis compares to the experimental measurement inferred by SPR. While the model predictions are much sparser (with the majority of antibody pairs uncategorized because the two model predictions were too close to one another), the classifications are nevertheless sufficient to group these antibodies by their epitopes. Antibodies \#1-3 all overlap with one another (and do not explicitly overlap with any other antibodies) and hence are assumed to bind one epitope. Antibodies \#4 and \#5 overlap with each other and form a second epitope group. Antibody \#6 did not explicitly overlap with any other antibody and forms a third epitope group. Lastly, Antibodies \#7-9 all overlapped with \#10, and hence these four antibodies bind to a fourth epitope. These four groups are shown by the dashed squares in [Fig 3A](#pcbi.1007830.g003){ref-type="fig"}, which only disagrees with the epitopes inferred by SPR (shown by the labels on the diagonal and determined using reference antibodies with known specificities) by claiming that Antibodies \#4-5 (rather than \#5-6) bind to an overlapping epitope.

These four epitope groups enable us to predict the activity of the 2-Ab and 3-Ab mixtures. Note that it is not the pairwise classification between two antibodies that determines whether we apply the distinct or competitive models, but rather the four groupings of antibody epitopes. For example, although antibodies \#7 and \#8 are uncategorized through their 2-Ab mixture, they fall within a single epitope group and hence are considered to bind competitively. Similarly, antibody \#1 and \#4 are modeled as binding independently because they belong to two distinct epitope groups.

Surprisingly, the results shown in [Fig 3B](#pcbi.1007830.g003){ref-type="fig"} have a coefficient of determination *R*^2^ = 0.90 that is on par with the results obtained using the SPR measurements ([Fig 2B](#pcbi.1007830.g002){ref-type="fig"}). Since the inferred epitope map relied on the 2-Ab activity data, we compared the predicted activity of the 3-Ab mixtures using the epitopes inferred through SPR with those inferred through the activity data and showed that they are nearly identical (*R*^2^ = 0.997, see [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section A.6). This suggests that there is no loss in the predictive power of the model when an epitope mapping is inferred through activity measurements.

![Classifying antibody epitopes as overlapping or distinct.\
(A) Comparing the experimentally measured activity to the overlapping or distinct epitope models enables us to characterize each antibody pair (provided the two models predict sufficiently different activities). The dashed squares represent the minimal epitope groupings inferred from this method. (B) The resulting predictions for the 2-Ab and 3-Ab mixtures have the same predictive power (*R*^2^ = 0.90) as a model that relies on epitope groupings given by SPR measurements ([Fig 2B](#pcbi.1007830.g002){ref-type="fig"}).](pcbi.1007830.g003){#pcbi.1007830.g003}

In summary, whether antibodies bind independently or competitively can be determined either: (1) directly through pairwise competition experiments or (2) by analyzing the activity of their 2-Ab mixtures in light of our two models. When this information is combined with the potency and dissociation constant of each antibody, the activity of an arbitrary mixture can be predicted. The Supplementary Information contains programs in both Mathematica and Python that can analyze either form of the pairwise interactions to determine the epitope grouping. If the characteristics of the individual antibodies are also provided, the program can predict the activity of any antibody mixtures at any specified ratio of the constituents.

Generalizing to models between purely competitive and purely independent binding {#sec006}
--------------------------------------------------------------------------------

Thus far, our model has treated each antibody pair as either binding independently (where the binding of a first antibody has no effect on the second) or binding competitively (where the two antibodies cannot be simultaneously bound). However, SPR experiments measuring the percent decrease of antibody binding in the presence of another blocking antibody can range between or beyond 0% and 100% ([Fig 4A](#pcbi.1007830.g004){ref-type="fig"}). We investigated whether incorporating this more nuanced level of interaction could further refine our characterization of these antibody mixtures.

To incorporate partial blocking between antibodies, we generalized the fractional activity of a 2-Ab mixture to $$\begin{array}{r}
{\text{Fractional}\mspace{720mu}\text{Activity} = \frac{1 + \alpha_{1}\frac{c_{1}}{K_{D}^{(1)}} + \alpha_{2}\frac{c_{2}}{K_{D}^{(2)}} + \alpha_{1}\alpha_{2}f_{12}\frac{c_{1}}{K_{D}^{(1)}}\frac{c_{2}}{K_{D}^{(2)}}}{1 + \frac{c_{1}}{K_{D}^{(1)}} + \frac{c_{2}}{K_{D}^{(2)}} + f_{12}\frac{c_{1}}{K_{D}^{(1)}}\frac{c_{2}}{K_{D}^{(2)}}},} \\
\end{array}$$ where *f*~12~ represents the fraction of simultaneous binding for both antibodies (for the *n* = 10 antibodies, these $\frac{n\left( n - 1 \right)}{2}$ parameters are set by $1 - \frac{\%\mspace{720mu}\text{in}\mspace{720mu}\text{Fig}\mspace{720mu} 4\text{A}}{100}$ clipped to lie between 0 and 1). In this way, the two antibodies can individually bind to EGFR as dictated by their individual dose-response curves, but the Boltzmann weight of their combined binding is decreased by their partial competition ($K_{D,\text{eff}}^{(2)} = \frac{K_{D}^{(2)}}{f_{12}}$ in [Fig 1C](#pcbi.1007830.g001){ref-type="fig"}). As expected, [Eq (4)](#pcbi.1007830.e018){ref-type="disp-formula"} reduces to independent binding when two antibodies do not inhibit one another's binding (*f*~12~ = 1) and to competitive binding when one antibody prevents the binding of another (*f*~12~ = 0). For reference, the values on the diagonal represent an antibody competing with itself, and deviations from 100% are likely attributed to noise (e.g. some of the blocking antibody falling off before the test antibody is introduced).

![A continuum model for antibody mixtures.\
(A) SPR blocking data from Koefoed *et al*. showing the percentage by which the presence of one antibody inhibits the binding of a second antibody \[[@pcbi.1007830.ref006]\]. (B) Characterizing the 2-Ab and 3-Ab mixtures using the continuous binding model [Eq (4)](#pcbi.1007830.e018){ref-type="disp-formula"} that incorporates the continuum of antibody blocking behavior. When antibodies \#8-10 are simultaneously bound, their potencies take on the modified values *α*~8,eff~ = 0.60, *α*~9,eff~ = 1.03, and *α*~10,eff~ = 0.97 (see [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section A.7).](pcbi.1007830.g004){#pcbi.1007830.g004}

Surprisingly, we found that this continuum model predicted the fractional activity of the 2-Ab and 3-Ab mixtures more poorly (*R*^2^ = 0.87; see [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section A.7) than the original model characterizing every antibody pair as either purely independent or competitive (*R*^2^ = 0.90; [Fig 2B](#pcbi.1007830.g002){ref-type="fig"}). More precisely, mixtures containing only Abs \#1-7 matched the model predictions far better than mixtures containing Abs \#8, \#9, or \#10 (Fig G in [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"}). Notably, Abs \#8-10 were the only antibodies that individually increased activity (*α* \> 1 in the A431NS cell line; Fig B Panel B in [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"}), yet when mixed with other antibodies they appeared to decrease EGFR activity. For example, while Abs \#8 and \#10 individually increase activity by 1.14 and 1.35, respectively, their mixture decreases activity to 0.65. This suggested that when Abs \#8-10 are simultaneously bound with another antibody, the mechanism of action by which they increase activity may be disrupted. This idea is corroborated by the observation that antibody mixtures containing Abs \#8-10 were systematically higher than the measured activity (Fig G Panel C in [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"}).

To account for this behavior, we modified the continuum model so that when antibodies \#8-10 were simultaneously bound with another antibody, their potency was modified to *α*~*j*,eff~ (in the most general form this adds one parameter for each of the *n* = 10 antibodies; however, we fixed *α*~*j*,eff~ = *α*~*j*~ for antibodies 1 ≤ *j* ≤ 7 whose potency is less than one). These parameter values were inferred from the antibody mixture data to be *α*~8,eff~ = 0.60, *α*~9,eff~ = 1.03, and *α*~10,eff~ = 0.97, and the resulting model predictions are substantially improved (*R*^2^ = 0.95; [Fig 4B](#pcbi.1007830.g004){ref-type="fig"}). Hence, although these antibodies increase activity when individually bound to EGFR, when another antibody is simultaneously bound to the receptor they either decrease activity (Ab \#8) or keep it essentially constant (Abs \#9-10). If Abs \#1-7 with individual potency less than 1 are also given *α*~*j*,eff~ values when simultaneously bound with another antibody, only 2/7 acquire an *α*~*j*,eff~ value that substantially differs from their individual potency parameter (see [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section A.7). This suggests that the mechanism of action for antibodies decreasing EGFR activity is often maintained even when they are simultaneously bound with other antibodies.

In summary, antibodies that individually enhance EGFR activity appear to behave differently (either decreasing activity or leaving it unchanged) when simultaneously bound with another antibody. In contrast, antibodies that individually decrease EGFR activity---likely by blocking ligand binding---will usually act exactly the same when simultaneously bound with another antibody.

Multidomain antibodies boost breadth and potency via avidity {#sec007}
------------------------------------------------------------

While the previous sections analyzed combinations of whole, unmodified antibodies, we now extend our framework to connect with the rising tide of engineering efforts that genetically fuse different antibody components to construct multi-domain antibodies \[[@pcbi.1007830.ref015]\]. Specifically, we focus our attention on recent work by Laursen *et al*. who isolated single-domain antibodies from llamas immunized with H2 or H7 influenza hemagglutinin (HA) \[[@pcbi.1007830.ref007]\]. The four single-domain antibodies isolated in this manner included one antibody that preferentially binds influenza A group 1 strains (Ab~A1~), another that binds influenza A group 2 strains (Ab~A2~), and two antibodies that bind to influenza B strains ($\text{Ab}_{\text{B}}^{(1)}$ and $\text{Ab}_{\text{B}}^{(2)}$). [Fig 5A and 5B](#pcbi.1007830.g005){ref-type="fig"} shows data from a representative influenza A group 1 strain (blue dot, only bound by the blue Ab~A1~), influenza A group 2 strain (green dot, only bound by the green Ab~A2~), and influenza B strain (gold dot, bound by both of the yellow $\text{Ab}_{\text{B}}^{(1)}$ and $\text{Ab}_{\text{B}}^{(2)}$ antibodies).

![Tethering influenza antibodies increases breadth and potency.\
(A) The influenza A antibodies Ab~A1~ and Ab~A2~ were tethered together to form Ab~A1~--Ab~A2~ while (B) two influenza B antibodies formed $\text{Ab}_{\text{B}}^{(1)} - \text{Ab}_{\text{B}}^{(2)}$. Representative data shown for an influenza A group 1 (blue), influenza A group 2 (green), and influenza B (gold) strains. Strong potency is marked by a small IC~50~ while large breadth implies that multiple strains are controlled by an antibody. (C) Representative states of HA and their corresponding Boltzmann weights for multidomain antibodies, where crosslinking between adjacent spikes boosts neutralization via avidity (*c*~eff~ = 1400 nM in [Eq (6)](#pcbi.1007830.e031){ref-type="disp-formula"}). (D) Theoretical predictions of the potency of all multidomain antibodies versus their measured values. The red points denote two outlier influenza strains discussed in the text that are not neutralized by Ab~A1~ or Ab~A2~ individually but are highly neutralized by their combination.](pcbi.1007830.g005){#pcbi.1007830.g005}

In the contexts of rapidly evolving pathogens such as influenza, two important characteristics of antibodies are their potency and breadth. Potency is measured by the inhibitory concentration IC~50~ at which 50% of a virus is neutralized, where a smaller IC~50~ represents a better antibody. Breadth is a measure of how many strains are susceptible to an antibody.

In an effort to improve the potency and breadth of their antibodies, Laursen *et al*. tethered together different domains using a flexible amino acid linker (right-most columns of [Fig 5A and 5B](#pcbi.1007830.g005){ref-type="fig"}) and tested them against a panel of influenza strains. To make contact with these multidomain constructs, consider a concentration *c* of the tethered antibody Ab~A1~--Ab~A2~. As derived in [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section C.1, the Ab~A1~ or Ab~A2~ portions of the antibody will neutralize the virus with relative probability $\frac{c}{\text{IC}_{50,\text{A1}}}$ or $\frac{c}{\text{IC}_{50,\text{A2}}}$, respectively, relative to the unbound HA state. Although neutralization is mediated by antibody binding, the two quantities may or may not be proportional \[[@pcbi.1007830.ref016]--[@pcbi.1007830.ref018]\], and hence the IC~50~s in the denominators need not equal the antibody dissociation constants.

Laursen *et al*. determined that their tethered constructs cannot intra-spike crosslink two binding sites on a single HA trimer, but they can inter-spike crosslink adjacent HA \[[@pcbi.1007830.ref007]\]. The linker connecting the two antibody domains facilitates such crosslinking, since when one domain is bound the other domain is confined to a smaller volume around its potential binding sites. This effect can be quantified by stating that the second domain has an effective concentration *c*~eff~ ([Fig 5C](#pcbi.1007830.g005){ref-type="fig"}, purple), making the relative probability of the doubly bound state $\frac{c}{\text{IC}_{50,\text{A1}}}\frac{c_{\text{eff}}}{\text{IC}_{50,\text{A2}}}$ (see [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section C.1). Therefore, the fraction of virus neutralized by two tethered antibody domains is given by $$\begin{array}{r}
{\text{Fraction}\mspace{720mu}\text{Neutralized} = \frac{\frac{c}{\text{IC}_{50,\text{A1}}} + \frac{c}{\text{IC}_{50,\text{A2}}} + \frac{c}{\text{IC}_{50,\text{A1}}}\frac{c_{\text{eff}}}{\text{IC}_{50,\text{A2}}}}{1 + \frac{c}{\text{IC}_{50,\text{A1}}} + \frac{c}{\text{IC}_{50,\text{A2}}} + \frac{c}{\text{IC}_{50,\text{A1}}}\frac{c_{\text{eff}}}{\text{IC}_{50,\text{A2}}}}.} \\
\end{array}$$

Note that this equation assumes that influenza virus is fully neutralized at saturating concentrations of antibody (*α* = 0 in [Eq (1)](#pcbi.1007830.e002){ref-type="disp-formula"}, with Fraction Neutralized analogous to 1 − Fractional Activity).

The IC~50~ of the tethered construct is defined as the concentration *c* at which half of the virus is neutralized, which can be solved to yield $$\begin{array}{r}
{\text{IC}_{50,\text{A}1 - \text{A}2} = \frac{\text{IC}_{\text{50,A1}}\,\text{IC}_{\text{50,A2}}}{c_{\text{eff}} + \text{IC}_{\text{50,A1}} + \text{IC}_{\text{50,A2}}},} \\
\end{array}$$ with an analogous expression holding for the $\text{Ab}_{\text{B}}^{(1)} - \text{Ab}_{\text{B}}^{(2)}$ construct. Using the measured IC~50~s of Ab~A1~-Ab~A2~ and $\text{Ab}_{\text{B}}^{(1)} - \text{Ab}_{\text{B}}^{(2)}$ against the various influenza strains, we can infer the value of the single parameter *c*~eff~ = 1400 nM. This result is both physically meaningful and biologically actionable, as it enables us to predict the IC~50~ of the tethered multidomain antibodies against the entire panel of influenza strains. [Fig 6A and 6B](#pcbi.1007830.g006){ref-type="fig"} compares the resulting predictions to the experimental measurements, where plot markers linked by horizontal line segments indicate a close match between the predicted and measured values.

The two tethered antibodies display unique trends that arise from their compositions. Since the two domains in Ab~A1~--Ab~A2~ bind nearly complementary strains, the tethered construct will increase breadth (since this multidomain antibodies can now bind to both group 1 and group 2 strains) but will only marginally improve potency. Mathematically, if Ab~A1~ binds tightly to an influenza A group 1 strain while Ab~A2~ binds weakly to this same strain (IC~50,A2~ → ∞), their tethered construct has an IC~50,A1-A2~ ≈ IC~50,A1~. Said another way, Ab~A1~--Ab~A2~ should be approximately as potent as a mixture of the individual untethered antibodies Ab~A1~ and Ab~A2~. Note that since the experiments could not accurately measure weak binding (\>1000 nM), the predicted IC~50~s for the multidomain antibodies represent a lower bound.

On the other hand, tethering the two influenza B antibodies yields a marked improvement in potency over either individual antibody, since both domains can bind to any influenza B strain and boost neutralization via avidity. The process of engineering a multivalent interaction is reminiscent of engineered bispecific IgG \[[@pcbi.1007830.ref015]\], and adding additional domains could yield further enhancement in potency, provided that all domains can simultaneously bind.

While the model is able to characterize the majority of tethered antibodies, it also highlights some of the outliers in the data. For example, the H3N2 strains A/Panama/2007/99 and A/Wisconsin/67/05 were poorly neutralized by either Ab~A1~ or Ab~A2~ (IC~50~ ≥ 1000 nM), but the tethered construct exhibited an IC~50~ = 14 nM and IC~50~ = 17 nM, respectively, far more potent than the 300 nM lower limit predicted for both viruses (red circles in [Fig 5D](#pcbi.1007830.g005){ref-type="fig"} and red lines in [Fig 6A](#pcbi.1007830.g006){ref-type="fig"}). Interestingly, Laursen *et al*. found that mixing the individual, untethered antibodies Ab~A1~ and Ab~A2~ also resulted in shockingly poor neutralization (IC~50~ ≥ 1000 nM), suggesting that the tether is responsible for the increase in potency \[[@pcbi.1007830.ref007]\]. From the vantage of our quantitative model, this outlier cries out for further investigation.

![Neutralization of multidomain antibodies.\
(A,B) The potency of the 2-Ab constructs and their constitutive antibodies against a panel of influenza strains. Ab~A1~ primarily binds influenza A group 1 (blue), Ab~A2~ to influenza A group 2 (green), and the two Ab~B~ antibodies to influenza B strains (gold). (C) All four antibodies were tethered to form the linear chain $\text{Ab}_{\text{A1}} - \text{Ab}_{\text{A2}} - \text{Ab}_{\text{B}}^{(1)} - \text{Ab}_{\text{B}}^{(2)}$ and (D) two copies of this chain were placed on an IgG backbone. The model suggests that the two arms of the IgG are not capable of simultaneously binding a virion. Red lines indicate two outlier influenza strains discussed in the text that are not neutralized by Ab~A1~ or Ab~A2~ individually but are highly neutralized by their combination. Data was digitized from Figs 1 and 3 of Ref \[[@pcbi.1007830.ref007]\].](pcbi.1007830.g006){#pcbi.1007830.g006}

To further boost neutralization, Laursen *et al*. created two additional constructs that combined all four antibody domains, the first being the linear chain ($\text{Ab}_{\text{A1}} - \text{Ab}_{\text{A2}} - \text{Ab}_{\text{B}}^{(1)} - \text{Ab}_{\text{B}}^{(2)}$). Since the influenza A antibodies do not bind the influenza B strains (and vise versa), this construct should have the same IC~50~ as Ab~A1~--Ab~A2~ for the influenza A strains and as $\text{Ab}_{\text{B}}^{(1)} - \text{Ab}_{\text{B}}^{(2)}$ for the influenza B strains, as was found experimentally (compare the *Predicted* columns in [Fig 6A--6C](#pcbi.1007830.g006){ref-type="fig"}). For example, the two H3N2 strains (A/Panama/2007/99 and A/Wisconsin/67/05) were again found to have measured IC~50~s (15 nM and 23 nM) far smaller than their predicted lower bound of 300 nM (red squares in [Fig 5D](#pcbi.1007830.g005){ref-type="fig"}, red lines in [Fig 6C](#pcbi.1007830.g006){ref-type="fig"}).

A second construct containing all four antibody domains attached two copies of $\text{Ab}_{\text{A1}} - \text{Ab}_{\text{A2}} - \text{Ab}_{\text{B}}^{(1)} - \text{Ab}_{\text{B}}^{(2)}$ through an IgG backbone ([Fig 6D](#pcbi.1007830.g006){ref-type="fig"}). Since the identical domains in both arms of this construct should be able to simultaneously bind, the new antibody should markedly boost potency through avidity. Surprisingly, the neutralization of this final construct was well characterized as half the IC~50~ of an individual $\text{Ab}_{\text{A1}} - \text{Ab}_{\text{A2}} - \text{Ab}_{\text{B}}^{(1)} - \text{Ab}_{\text{B}}^{(2)}$, suggesting that there was no noticeable avidity and that the increase in neutralization only arose from having twice as many antibody domains. As above, this intriguing result presents an opportunity to both quantitatively check experimental results and to advocate for future studies. In this particular instance, it suggests that the IgG backbone used was not able to simultaneously bind with both arms. If a different multivalent scaffold (perhaps with greater flexibility or with longer linkers) enabled bivalent binding of both linear antibody chains, it could potentially increase the neutralization of this construct by 100-fold as seen in the influenza B constructs.

Discussion {#sec008}
==========

In this work, we developed a statistical mechanical model that predicts the collective efficacy of an antibody mixture whose constituents are assumed to bind to a single site on a receptor. Each antibody is first individually characterized by its ability to bind the receptor (through its dissociation constant *K*~*D*~) and inhibit activity (via its potency *α*) as per [Eq (1)](#pcbi.1007830.e002){ref-type="disp-formula"}. Importantly, this implies that the activity of each monoclonal antibody must be measured at a minimum of two concentrations in order to infer both parameters, and additional measurements would further refine these parameter values and the corresponding model predictions.

After each antibody is individually characterized, the activity of a combination of antibodies will depend upon whether they bind independently to distinct epitopes or compete for overlapping epitopes. Theoretical models often assume for simplicity that all antibodies bind independently, and in the contexts where this constraint can be experimentally imposed such models can accurately predict the effectiveness of antibody mixtures \[[@pcbi.1007830.ref009]\]. Yet when the antibody epitopes are unknown or when a large number of antibodies are combined, it is likely that some subset of antibodies will compete with each other while others will bind independently, which will give rise to a markedly different response. Our model generalized these previous results to account for antibody mixtures where arbitrary subsets can bind independently or competitively (Eqs [(2)](#pcbi.1007830.e011){ref-type="disp-formula"} and [(3)](#pcbi.1007830.e012){ref-type="disp-formula"}, [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section A.2).

We showed that in the context of the EGFR receptor, where every pairwise interaction was measured using surface plasmon resonance, our model is better able to predict the efficacy of all 2-Ab and 3-Ab mixtures than a model that assumes all antibodies bind independently or competitively ([Fig 2](#pcbi.1007830.g002){ref-type="fig"}). This suggest that mixtures of antibodies do not exhibit large synergistic effects. More generally, similar models in the contexts of anti-cancer drug cocktails and anti-HIV antibody mixtures also found that the majority of cases that were described as synergistic could instead be characterized by an independent binding model \[[@pcbi.1007830.ref009], [@pcbi.1007830.ref010]\]. This raises the possibility that synergy is more the exception then the norm, and hence that simple models can computationally explore the full design space of antibody combinations.

While it is often straightforward to measure the efficacy of *n* individual antibodies, it is more challenging to quantify all $\frac{n\left( n + 1 \right)}{2}$ pairwise interactions and determine which antibodies bind independently and which compete for an overlapping epitope. We demonstrated that after each antibody is individually characterized, our model can be applied in reverse by using the activity of 2-Ab mixtures to classify whether antibodies compete or bind independently ([Fig 3](#pcbi.1007830.g003){ref-type="fig"}). Surprisingly, while the resulting categorizations were much sparser than the direct SPR measurements, the classifications produced by this method predicted the efficacy of antibody combinations with an *R*^2^ = 0.90, comparable to the predictions made using the complete SPR results ([Fig 2B](#pcbi.1007830.g002){ref-type="fig"}). This suggests that key features of how antibodies interact on a molecular level can be indirectly inferred from simple activity measurements of antibody combinations.

Although these models classified antibody epitopes as either distinct or overlapping, SPR measurements indicate that there is a continuum of possible interactions. Surprisingly, when we generalized our binding model to explore this broader class of behaviors, we found that it resulted in poorer model predictions ([S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section A.7). More specifically, the three antibodies (\#8-10) that individually increased EGFR activity seemed to decrease activity when simultaneously bound with another antibody, representing an important form of synergy that was neglected in the previous simpler models. To account for this behavior, we introduced *n* = 10 effective potency parameters *α*~*j*,eff~ (one per antibody) to quantify the potency of each antibody when simultaneously bound with another antibody. Rather than fitting each of these parameters to the data, we found that fixing *α*~*j*,eff~ = *α*~*j*~ for antibodies satisfying 1 ≤ *j* ≤ 7 (whose individual potency was less than one) and only fitting *α*~*j*,eff~ for the three antibodies that individually increased fractional activity led to a substantial improvement in the model ([Fig 4](#pcbi.1007830.g004){ref-type="fig"}). The effective potency of all three antibodies was reduced by at least 15%, corroborating the notion that when simultaneously bound with another antibody, their effect on EGFR activity may differ from when these antibodies are individually bound ([S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section A.7).

Modern bioengineering has opened up a new avenue of mixing antibodies by genetically fusing different components to construct multi-domain antibodies \[[@pcbi.1007830.ref015]\]. Such antibodies can harness multivalent interactions to greatly increase binding avidity by over 100-fold (as seen by the IC~50~s of the A/Wisconsin/67/05 and B/Harbin/7/94 strains in [Fig 6](#pcbi.1007830.g006){ref-type="fig"}). For such constructs, the composition of the linker can heavily influence the ability to multivalently bind and neutralize a virus \[[@pcbi.1007830.ref018], [@pcbi.1007830.ref019]\], although Laursen *et al*. surprisingly found little variation when they modified the length of their amino acid linker (see Table S11 in Ref \[[@pcbi.1007830.ref007]\]). Another curious feature of their system was that placing their linear 4-domain antibody ([Fig 6C](#pcbi.1007830.g006){ref-type="fig"}) on an IgG backbone ([Fig 6D](#pcbi.1007830.g006){ref-type="fig"}) only resulted in a 2-fold decrease in IC~50~, suggesting that the two "arms" of the IgG could not simultaneously bind. We would expect that a different backbone that allows both arms to simultaneously bind would markedly increase the neutralization potency of this construct. In this way, quantitatively modeling these multidomain antibodies can guide experimental efforts to design more potent constructs.

Methods {#sec009}
=======

Models of EGFR antibody binding {#sec010}
-------------------------------

Antibody mixtures from Ref. \[[@pcbi.1007830.ref006]\] were first characterized using a binding model (Eqs [(2)](#pcbi.1007830.e011){ref-type="disp-formula"} and [(3)](#pcbi.1007830.e012){ref-type="disp-formula"} for 2-Ab mixtures; Eqs (S6)-(S8) for 3-Ab mixtures) where every antibody pair either binds independently or dependently. Model parameters are given in Fig B Panel B of [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"}.

Antibody epitopes were determined using SPR blocking data ([Fig 3A](#pcbi.1007830.g003){ref-type="fig"}, bottom-left), with two antibodies categorized as overlapping if the average of the two antibody measurements (with preincubation by either antibody) were \> 50% and as distinct if the average was \< 50% (exact values given in [Fig 4A](#pcbi.1007830.g004){ref-type="fig"}). The reverse process using the antibody mixture data to determine whether antibodies have distinct or overlapping epitopes is described in [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section B.

A continuum model that incorporates partial competition between each pair of antibodies (Eq (S9) for 2-Ab mixtures; Eq (S10) for 3-Ab mixtures) is described in [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section A.7. In this model, antibodies are allowed to partially compete for the same epitope ([Fig 1C](#pcbi.1007830.g001){ref-type="fig"}) with the amount of competition dictated by SPR blocking data ([Fig 4A](#pcbi.1007830.g004){ref-type="fig"}).

Models for influenza multidomain antibodies {#sec011}
-------------------------------------------

Influenza multidomain antibodies from Ref. \[[@pcbi.1007830.ref007]\] were characterized using a neutralization model derived in [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"} Section C.1, Eq (S17). Combining a binding model that accounts for the avidity of the multiple domains together with a sigmoidal relationship between binding and neutralization \[[@pcbi.1007830.ref017]\], we derive an expression for the neutralization of these multidomain antibodies. Assuming a Hill coefficient of 1 between binding and neutralization, this model is identical to the distinct binding model used for EGFR antibodies (1 − Fractional Activity in [Eq (2)](#pcbi.1007830.e011){ref-type="disp-formula"}) with potency *α*~*j*~ = 0 for each antibody domain, *K*~*D*~ → IC~50~, and *c*~2~ → *c*~eff~.

Goodness of fit {#sec012}
---------------

The coefficient of determination used to quantify how well the theoretical predictions matched the experimental measurements (relative to the dashed line *y* = *x* in Figs [2B--2D](#pcbi.1007830.g002){ref-type="fig"}, [3B](#pcbi.1007830.g003){ref-type="fig"}, [4B](#pcbi.1007830.g004){ref-type="fig"} and [5D](#pcbi.1007830.g005){ref-type="fig"}) was calculated using $$\begin{array}{r}
{R^{2} = 1 - \frac{\sum_{j = 1}^{n}\left( y_{\text{measured}}^{(j)} - y_{\text{predicted}}^{(j)} \right)^{2}}{\sum_{j = 1}^{n}\left( y_{\text{data}}^{(j)} \right)^{2}}} \\
\end{array}$$ where *y*~measured~ and *y*~predicted~ represent a vector of the measured and predicted activities for the *n* mixtures analyzed. In [Fig 5D](#pcbi.1007830.g005){ref-type="fig"}, we computed the *R*^2^ of log~10~(activity) to prevent the largest activities from dominating the result (since the IC~50~ values span multiple decades).

Experimental data {#sec013}
-----------------

All data are available in the Supporting Information [S1 File](#pcbi.1007830.s002){ref-type="supplementary-material"}. Data from the EGFR antibody mixtures was obtained by digitizing Ref \[[@pcbi.1007830.ref006]\] Fig S1 using WebPlotDigitizer \[[@pcbi.1007830.ref020]\]. Data for the influenza multidomain antibodies was obtained from the authors of Ref \[[@pcbi.1007830.ref007]\]. The original nomenclature for the antibodies used in Koefoed *et al*. and Laursen *et al*. are given in Table A in [S1 Text](#pcbi.1007830.s001){ref-type="supplementary-material"}.

Supporting information {#sec014}
======================

###### Aforementioned derivations and discussions.

(PDF)

###### 

Click here for additional data file.

###### Contains all of the data analyzed in this work.

(ZIP)

###### 

Click here for additional data file.

###### A supplementary Mathematica notebook contains the data analyzed in this work, recreates all plots shown, and contains a program that takes in the activity of individual antibodies and their pairwise interactions and predicts the activity of all mixtures.

(ZIP)

###### 

Click here for additional data file.

###### A supplementary Python notebook analogous to [S2 File](#pcbi.1007830.s003){ref-type="supplementary-material"}.

(ZIP)

###### 

Click here for additional data file.
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Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: A cocktail of antibodies can be a superior treatment in comparison to single monoclonal antibodies, but understanding the mechanisms behind this observation is still missing. The manuscript by Einav et al. proposes a framework for prediction of the activity of the mixture of antibodies based on measured parameters of individual antibodies (such as affinity, activity and epitope mapping), and, thus, the manuscript addresses an important question. Authors used several experimental data sets to verify their model predictions, and their analysis reports interesting results.

Although the manuscript is well written, and I enjoyed reading it, it has some limitations that need to be addressed before its publication:

1\. The model introduced parameter "alpha" (in lines 48-49 and S1 text) ranging 0-1, where alpha=1 corresponds to no effect and alpha=0 implies complete inhibition of receptor activity upon binding by antibody. Underlying model assumes the monotonic relationship between binding of EGFR receptor by growth factors and activation of the cells, where no activation will be seen if all EGFR receptors are blocked by antibodies.

The problem appears when parameter "alpha" is estimated in Figure S2. Parameter "alpha"\<1 for all 10 antibodies was derived for HN5 line, but \>1 for three antibodies for A431NS. "alpha"\>1 corresponds to the case where blocking of all EGFR receptors with antibodies will lead to maximal cell growth. Comparison of "alpha" values for HN5 and A431NS for these three antibodies suggests that the key hidden assumption of the model about monotonic relationship between binding of EGFR receptors by growth factors and activation of the cells is somehow not true (at least for these three antibodies and used concentrations).

One way to deal with it is to analyze only 7 antibodies. Will it lead to better overall predictions in Figure 2C? Currently, model predicts higher fractional activity than measured for many antibody mixtures. Will it still be true if only 7 antibodies and their mixtures will be used in the analysis?

2\. What is R2 in Figure 2B-D correspond to? Is it for comparison of the model predictions to the data (shown line y=x) or for the overall best fit of the data (y=ax+b, which is a different case and, in this case, it will be interesting to see parameters a and b)?

3\. please include the original experimental data as requested by the journal policy (for example, measured values for fractional activity data for Figure 2B) in the supplemental information

Minor

1\. p.4 line 72 "and their epitopes are mapped" add "by pairwise interactions"

2\. suggestion for Figure 2B \-- to change "2/3Abs" (it reads "two thirds of Abs" which is confusing) to "2Abs/3Abs" and additionally define circles and triangles somewhere in the text

3\. few typos: see lines 146, 220 in main text and first sentence on p. S2

Reviewer \#2: This paper addresses the timely topic of complex antibody-antigen interactions mediated by two or more antibodies simultaneously present. The authors take a clear biophysical modelling approach to predict the binding activity of antibody mixtures to EGFR and show that the model using epitope mapping data indeed improves upon models assuming only independent or competitive binding. I have the following observations:

1\. The basic modelling approach is not new. A model introduced by Wagh et al., PLoS Pathogens, 2016 also considers competitive and independent binding and seems to have large overlap. Can the authors comment on how their model is different?

2\. The authors mention possible avenues to extend the basic model for antibody binding. In particular, synergy between antibodies can boost their activity with 10% and note that a more \'nuanced level of interaction\' between antibodies could lead to a more precise prediction of dissociation constants. An extension of the binding model is, however, not pursued. In view of comment 1, I feel that an attempt to include \'a continuum of possible interactions\' to the binding model could greatly improve the novelty of the modelling approach taken by the authors.

3\. Another important point of the manuscript is that multidomain antibodies boost breadth and potency via avidity. However, avidity and boost free energies are not clearly integrated into the basic biophysical model and the corresponding discussion remains somewhat imprecise. I would suggest to integrate the notion of avidity already at the level of equations (2) and (3).

4\. The authors motivate their study of antibody mixtures by stating that \'mounting evidence suggests that mixtures of antibodies can behave in fundamentally different ways \[2\]\'. Does this refer to the competitive or independent binding dynamics of mixtures? The clinical trials that are mentioned in this reference only investigate bnAb-combinations with non-overlapping target sites, such that independent binding dynamics apply.

5\. From Fig. 5 on the prediction of IC50\'s of multi-domain antibodies, it is difficult to quantify the prediction of the model. Can the authors quantify how well you can predict the IC50 of the multi domain antibodies, and how much the model improves on an uninformed binding model?

Reviewer \#3: Motivated by the increasing popularity of combination antibody therapy, the authors developed an equilibrium binding model to describe the effect of an antibody mixture on the activity of a multi-epitope protein, and applied this model to published data sets on a cancer-related receptor and influenza viral proteins. By assuming either independent or exclusive binding of antibodies, the authors calculated the effect of antibody combinations, using measurements of individual antibodies and pairwise interactions or epitope mapping as inputs. They further considered engineered multi-domain antibodies and compared the predicted and measured potency.

My comments are as follows:

1\. The authors claimed that 'the power of this model lies in its ability to make a large number of predictions based on a limited amount of data. For example, once 10 antibodies have been individually characterized, our model can predict how any of the 2\^10=1024 combinations will behave.' This is not true, given that either pairwise measurements or information of epitope mapping has to be provided. More importantly, the assumption of either independent or exclusive binding seems not properly validated; e.g. as shown in Fig. 2A, prediction and measurement do not show a good match. In addition, the measured activity is systematically lower than the predicted value. Both observations indicate potential importance of synergistic effect which is neglected in the analysis. Synergistic effects (e.g. through allostery) could be even more prominent in compliant protein molecules, which might restrict the generality of this model. This issue should be directly addressed.

2\. The authors stated that deviations from the predictions provide a rigorous way to measure antibody synergy, but no analysis is provided to support this statement. It would be more convincing to directly demonstrate this measure for the datasets used. This may offer a metric for the predictive power of this simplified model.

3\. 'This predictive power paves the way to expedite the design of future therapeutics'. This is a superfluous statement. I urge the authors to discuss in concrete terms what general design principles are learnt from this study.

4\. In Fig. 3A, it seems that the model fails to predict the epitope of most of the pairs, because two models predict very similar activities. And yet, this lack of epitope information doesn't impair the correlation between measured and predicted activity (Fig. 3B). Isn't this showing the model is not well constrained and lacking predictive power?

5\. The outliers in Fig. 5 are glaring. Analysis with synergistic effect should be added to show whether remedy can be achieved.

6\. As the author pointed out, SPR measurements indicate that there is a continuum of possible interactions, how this aspect shall be accounted for while still maintaining the simplicity and hence scalability of the model should be discussed in depth.

7\. The main text is hard to follow without frequently referring to the SI text. The Methods section in the main text should be expanded to include the essential information and formula for each subsection in Results.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Computational Biology* [data availability policy](http://journals.plos.org/ploscompbiol/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.
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Very nice paper in a very interesting area \.... please take care of the typos indicated.  Best regards, rustom

Dear Dr Bloom,

We are pleased to inform you that your manuscript \'When two are better than one: Modeling the mechanisms of antibody mixtures\' has been provisionally accepted for publication in PLOS Computational Biology.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution\'s press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Computational Biology. 

Best regards,

Rustom Antia

Associate Editor

PLOS Computational Biology

Alice McHardy

Deputy Editor

PLOS Computational Biology

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Reviewer\'s Responses to Questions

**Comments to the Authors:**

**Please note here if the review is uploaded as an attachment.**

Reviewer \#1: The authors did significant revisions of the manuscript in response to Reviewers comments.

All my concerns have been addressed. It is a well-written, well-organized paper, and I recommend it for publication.

Reviewer \#2: The authors have addressed all of my points in a satisfactory manner. I believe that the extensive revision has significantly improved the manuscript and I am particularly impressed by the new section on the continuum model, in which the authors show that antibodies can behave differently when they are simultaneously bound. The paper is ready for publication, there are two minor points that could be addressed in the final version:

1\. The fraction f, as introduced in the new section on the continuum model, represents the fraction of simultaneous binding for both antibodies. Fig. 4A shows 1-f for the antibodies in the study. I find it striking that the values on the diagonal are not all at 100%, meaning that the antibodies do not completely block themselves. Could the authors comment on this interesting observation?

2\. There appears to be a minor error in the SI, section C.1: Before Eq. S13, it is stated that \"It has been proposed that neutralisation is a sigmoidal function of neutralisation\", which probably should have been the number of IgG bound.

Reviewer \#3: The authors have addressed all my questions esp. regarding the synergistic effect and have carried out additional computation to generalize the model to be applicable for a continuum of competition strength. I can now support the publication of this manuscript.

\*\*\*\*\*\*\*\*\*\*

**Have all data underlying the figures and results presented in the manuscript been provided?**

Large-scale datasets should be made available via a public repository as described in the *PLOS Computational Biology* [data availability policy](http://journals.plos.org/ploscompbiol/s/data-availability), and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer \#1: Yes

Reviewer \#2: None

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/ploscompbiol/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Michael Lässig

Reviewer \#3: No

10.1371/journal.pcbi.1007830.r004

Acceptance letter

McHardy

Alice Carolyn

Deputy Editor

Antia

Rustom

Associate Editor

© 2020 McHardy, Antia

2020

McHardy, Antia

This is an open access article distributed under the terms of the

Creative Commons Attribution License

, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

20 Apr 2020

PCOMPBIOL-D-19-01827R1

When two are better than one: Modeling the mechanisms of antibody mixtures

Dear Dr Bloom,

I am pleased to inform you that your manuscript has been formally accepted for publication in PLOS Computational Biology. Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out, the early version of your manuscript will be published online. The date of the early version will be your article\'s publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Computational Biology and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Laura Mallard

PLOS Computational Biology \| Carlyle House, Carlyle Road, Cambridge CB4 3DN \| United Kingdom <ploscompbiol@plos.org> \| Phone +44 (0) 1223-442824 \| [ploscompbiol.org](http://ploscompbiol.org) \| \@PLOSCompBiol

[^1]: The authors have declared that no competing interests exist.
